Clinical Trial Update: A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating TQB2450 in combination with Anlotinib in gynecological cancer across Phase 1 and Phase 2 stages; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecological Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Gynecological Cancer | Phase 1, Phase 2 | Status: UNKNOWN